Bridging the Gap: How Community Education Boosts Clinical Trial Awareness
According to a report by Medical Xpress, physician-researchers in South Florida are testing whether community education can help more people learn about and consider clinical trials.
The study is relevant beyond the outreach sessions themselves: it points to a workflow problem in oncology and primary care—patients cannot consider a trial if nobody explains that one may be available or connects them with the research team.
Education improved interest, but not access
The study was conducted by researchers from Florida International University and Baptist Health, with Dr. Leanne Dumeny working through the FIU/Baptist Health Family Medicine Residency. The team held two English-language sessions in Palm Beach and Broward counties and one Spanish-language session in Miami-Dade County.
The presentations explained what clinical trials are, why they matter and how people can become involved. Testimonial speakers also described their own experiences, an approach intended to make the subject more understandable for attendees.
A total of 115 adults completed anonymous surveys before and after the sessions. Afterward, 96% said the presentations had improved their understanding of clinical trials, while 77% said they were more willing to participate in future studies.
Those figures suggest that information can shift attitudes. But the more operational finding is that roughly one-quarter of participants were interested in joining a trial and had never been offered the opportunity. Education may open the door; it does not, by itself, provide the referral, eligibility review or connection to an active study.
That gap matters in a field where participation remains limited. The report says only about 7% of U.S. adults with cancer enroll in treatment-related clinical trials.
The missing link is inside the care workflow
The researchers’ conclusion is practical: health systems and research programs need pathways that connect interested people with available studies. For a patient, that means a public presentation is only the first step. The next question is whether the clinic has a clear process for identifying relevant trials and passing the patient to the appropriate research team.
The study also calls for clinicians to ask every patient about interest in clinical trials, rather than making assumptions about who might say yes. That recommendation places the issue directly inside routine care. It is not enough for a physician to know that trials exist in general; the practice must also know which studies are available and be prepared to discuss them.
For independent practices and smaller clinics, this is where workflow integration becomes decisive. A trial conversation requires time, current information and a defined handoff. Without those elements, an interested patient may leave with better general knowledge but no practical route to participation.
The report does not establish that the sessions increased enrollment in a trial. It measured understanding and willingness after the presentations. That distinction is important: interest is an access signal, not proof that a patient is eligible or that a study will be appropriate.
What patients should verify before deciding
Patients considering a clinical trial should first ask the clinic which specific study is being discussed and whether the research team has reviewed their situation. The available report does not provide a standard checklist of documents or participation conditions, so those details must come from the treating clinician or study staff.
It is also reasonable to clarify how the clinic will connect the patient with the trial team. The study’s central finding is that people may be interested yet never receive an offer, making the referral pathway as important as the initial explanation.
Language access is another confirmed feature of the South Florida approach: sessions were offered in both English and Spanish. That does not prove that every trial provides materials or staff in both languages, but it shows why communication format matters when researchers are trying to reach a broader patient population.
The larger issue is representation. The researchers argue that improving understanding and willingness could bring a more diverse group of people into clinical trials, helping researchers see how treatments work across different populations. For physicians, the immediate test is not whether they can describe research in the abstract. It is whether their practice can identify an available study, discuss it without assumptions and complete the handoff before the opportunity disappears.